Arch Biopartners IncOTCQB:ACHFFView on Canadian Exchange
- LAST PRICE1.3800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2900/ 2
- Ask / Lots1.4100/ 1
- Open / Previous Close--- / 1.3800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACHFF |
|---|---|---|
| 09:46 ET | 300 | 1.352 |
| 01:06 ET | 400 | 1.325 |
| 02:14 ET | 600 | 1.3101 |
| 03:32 ET | 1000 | 1.355 |
| 03:44 ET | 2800 | 1.36 |
| 03:53 ET | 800 | 1.37 |
| 03:55 ET | 400 | 1.38 |
| 04:00 ET | 1200 | 1.38 |
Nov 11, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arch Biopartners Inc | 124.8M | --- | --- |
Company Information
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
Contact Information
- Headquarters
- 545 King St W.TORONTO, ON, Canada M5X 1A1
- Phone
- 647-428-7031
- Fax
- 647-351-3565
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $124.8M |
|---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 64.7M |
Arch Biopartners Inc does not pay a dividend. | |
Beta | 0.93 |
EPS | $-0.04 |
Book Value | $-0.09 |
P/E Ratio | --- |
Price/Sales (TTM) | 90.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -173.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
